Sirolimus as a potential radiosensitizer in squamous cell cancer of the head and neck

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Head and Neck

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hed.20898PMID 18704962PMCID PMC2737255
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

  2007cited by this paper
• Phase I Trial of Sirolimus Combined with Radiation and Cisplatin in Non-small Cell Lung Cancer

  2007cited by this paper
• Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: possible role for thrombosis.

  2007cited by this paper
• Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.

  2006cited by this paper
• Sirolimus Conversion for Patients with Posttransplant Kaposi's Sarcoma

  2006cited by this paper
• Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer

  2006cited by this paper
• Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.

  2006cited by this paper
• Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy.

  2006cited by this paper
• A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

  2006cited by this paper
• Population Pharmacokinetics of CCI‐779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer

  2005cited by this paper
• Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

  2005cited by this paper
• Enhanced radiation damage of tumor vasculature by mTOR inhibitors

  2005cited by this paper
• CCI‐779 in metastatic melanoma

  2005cited by this paper
• Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

  2005cited by this paper
• Sirolimus for Kaposi's sarcoma in renal-transplant recipients.

  2005cited by this paper
• Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

  2005cited by this paper
• Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

  2005cited by this paper
• Upstream and downstream of mTOR.

  2004cited by this paper
• CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.

  2004cited by this paper
• Persistent Activation of the Akt Pathway in Head and Neck Squamous Cell Carcinoma

  2004cited by this paper
• Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

  2004cited by this paper
• Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival

  2004cited by this paper
• Sirolimus for pediatric liver transplant recipients with post‐transplant lymphoproliferative disease and hepatoblastoma *

  2004cited by this paper
• Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

  2004cited by this paper
• Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

  2002cited by this paper
• Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.

  2002cited by this paper
• Molecular Analysis of Surgical Margins in Head and Neck Squamous Cell Carcinoma Patients

  2002cited by this paper
• Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation.

  2001cited by this paper
• Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.

  1999cited by this paper
• Pattern of amplification and overexpression of the eukaryotic initiation factor 4E gene in solid tumor.

  1999cited by this paper
• Blockade of the Vascular Endothelial Growth Factor Stress Response Increases the Antitumor Effects of Ionizing Radiation

  1999cited by this paper

• ESMO-ESTRO consensus statements on the safety of combining radiotherapy with CDK4/6, HER2, PARP, or mTOR inhibitors.

  2025cites this paper
• Guidelines about radiotherapy and oncologic systemic treatments: Stop or continue?

  2025cites this paper
• Key signalling pathways in head and neck squamous cell carcinoma: mechanisms and therapeutic targets.

  2025cites this paper
• Cutting-Edge Technology Without Cutting: Treating Skin Cancer in This Era—A Case Series

  2024cites this paper
• Rapamycin alleviates irradiation-induced parotid injury by enhancing the whole gland homeostasis.

  2024cites this paper
• Cutaneous squamous cell carcinoma in solid organ transplant recipients: Current therapeutic and screening strategies.

  2024cites this paper
• Interactions of radiation therapy with common and innovative systemic treatments: Antidiabetic treatments, antihypertensives, lipid-lowering medications, immunosuppressive medications and other radiosensitizing methods.

  2022cites this paper
• Responsive nanomedicines enhanced by or enhancing physical modalities to treat solid cancer tumors: Preclinical and Clinical evidence of safety and efficacy.

  2021cites this paper
• Systematic review of sirolimus in dermatological conditions

  2021cites this paper
• Cutaneous squamous cell carcinoma in the organ transplant recipient.

  2020cites this paper
• Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors

  2019cites this paper
• mTOR-Mediated Antioxidant Activation in Solid Tumor Radioresistance

  2019cites this paper
• [Radiotherapy and immune suppression: A short review].

  2019cites this paper
• Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC)

  2018cites this paper
• Nanomedicine approaches for sirolimus delivery: a review of pharmaceutical properties and preclinical studies

  2018cites this paper
• m-TOR inhibitor as potential radiosensitizer for head and neck squamous cell carcinoma: A case report of an organ transplant patient and review of the literature.

  2016cites this paper
• Early and Severe Radiation Esophagitis Associated With Concurrent Sirolimus.

  2016cites this paper
• Radiosensitization of oral tongue squamous cell carcinoma by nanosecond pulsed electric fields

  2016cites this paper
• Early and Severe Radiation Toxicity Associated with Concurrent Sirolimus in an Organ Transplant Recipient with Head and Neck Cutaneous Squamous Cell Carcinoma: A Case Report.

  2015cites this paper
• The PI3K Signaling Pathway in Head and Neck Squamous Cell Carcinoma

  2014cites this paper
• Integration of molecular targeted therapy with radiation in head and neck cancer.

  2014cites this paper
• High mTOR expression is associated with a worse oncological outcome in laryngeal carcinoma treated with postoperative radiotherapy: a pilot study.

  2012cites this paper
• mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multivariate analyses.

  2012cites this paper
• Disrupting the mTOR signaling network as a potential strategy for the enhancement of cancer radiotherapy.

  2012cites this paper
• Effects and Therapeutic Potential of Targeting Dysregulated Signaling Axes in Squamous Cell Carcinoma: Another Kinase of Transcription and Mammalian Target of Rapamycin

  2011cites this paper
• Efficacy and Comparative Effectiveness of Sirolimus (Rapamune) as an Anticancer Drug

  2011cites this paper
• The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts.

  2011cites this paper
• Efficacy and comparative effectiveness of sirolimus as an anticancer drug

  2011cites this paper